A Manatt team led by Capital Markets Partner Thomas J. Poletti represented Alliance Global Partners (A.G.P.) as the underwriter for Chromocell Therapeutics Corp.'s initial public offering (IPO), which raised $6.6 million. Chromocell Therapeutics, a company based in New Jersey, develops and sells non-opioid and non-addictive treatments for pain and other related medical conditions. Their IPO consisted of 1.1 million shares of their stock, priced at $6 each. It began trading on the New York Stock Exchange under the ticker symbol “CHRO.” The Manatt team also included Corporate and Finance Partner Veronica Lah and Corporate and Finance Associate Danli Lan.
Chromocell plans to primarily utilize net profits for research on their medication, CC8464. Any extra funds will be directed towards fulfilling the company's overall business requirements.
To learn more about the deal, click here.